TY - JOUR
T1 - Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1
AU - Isakson, Sara H.
AU - Rizzardi, Anthony E.
AU - Coutts, Alexander W.
AU - Carlson, Daniel F.
AU - Kirstein, Mark N.
AU - Fisher, James
AU - Vitte, Jeremie
AU - Williams, Kyle B.
AU - Pluhar, G. Elizabeth
AU - Dahiya, Sonika
AU - Widemann, Brigitte C.
AU - Dombi, Eva
AU - Rizvi, Tilat
AU - Ratner, Nancy
AU - Messiaen, Ludwine
AU - Stemmer-Rachamimov, Anat O.
AU - Fahrenkrug, Scott C.
AU - Gutmann, David H.
AU - Giovannini, Marco
AU - Moertel, Christopher L.
AU - Largaespada, David A.
AU - Watson, Adrienne L.
N1 - Publisher Copyright:
© 2018, The Author(s).
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Neurofibromatosis Type 1 (NF1) is a genetic disease caused by mutations in Neurofibromin 1 (NF1). NF1 patients present with a variety of clinical manifestations and are predisposed to cancer development. Many NF1 animal models have been developed, yet none display the spectrum of disease seen in patients and the translational impact of these models has been limited. We describe a minipig model that exhibits clinical hallmarks of NF1, including café au lait macules, neurofibromas, and optic pathway glioma. Spontaneous loss of heterozygosity is observed in this model, a phenomenon also described in NF1 patients. Oral administration of a mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor suppresses Ras signaling. To our knowledge, this model provides an unprecedented opportunity to study the complex biology and natural history of NF1 and could prove indispensable for development of imaging methods, biomarkers, and evaluation of safety and efficacy of NF1-targeted therapies.
AB - Neurofibromatosis Type 1 (NF1) is a genetic disease caused by mutations in Neurofibromin 1 (NF1). NF1 patients present with a variety of clinical manifestations and are predisposed to cancer development. Many NF1 animal models have been developed, yet none display the spectrum of disease seen in patients and the translational impact of these models has been limited. We describe a minipig model that exhibits clinical hallmarks of NF1, including café au lait macules, neurofibromas, and optic pathway glioma. Spontaneous loss of heterozygosity is observed in this model, a phenomenon also described in NF1 patients. Oral administration of a mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor suppresses Ras signaling. To our knowledge, this model provides an unprecedented opportunity to study the complex biology and natural history of NF1 and could prove indispensable for development of imaging methods, biomarkers, and evaluation of safety and efficacy of NF1-targeted therapies.
UR - http://www.scopus.com/inward/record.url?scp=85061883680&partnerID=8YFLogxK
U2 - 10.1038/s42003-018-0163-y
DO - 10.1038/s42003-018-0163-y
M3 - Article
C2 - 30302402
AN - SCOPUS:85061883680
SN - 2399-3642
VL - 1
JO - Communications Biology
JF - Communications Biology
IS - 1
M1 - 158
ER -